Results 11 to 20 of about 16,624 (211)

How Can Pharmacology Help Us Overcome the Challenges of Drug Repositioning as Antivirals to Treat Emerging Pathogens? The Example of Covid-19. [PDF]

Clin Transl Sci
Pharmacological pitfalls and challenges in drug repurposing for emerging pathogens: lessons from COVID‐19. ABSTRACT The Covid‐19 pandemic highlighted the urgent need for effective therapies against emerging pathogens. Drug repurposing, defined as the use of existing medications for new therapeutic purposes, was extensively pursued for SARS‐CoV‐2 but ...
Ben Ghezala I, Peiffer-Smadja N, Solas C, Nougairède A, Touret F, Bardou M.   +5 more
europepmc   +2 more sources

A brief overview of current drug repurposing approaches for COVID-19 management [PDF]

, 2020
This brief overview is intended to shed light on the current drug repositioning (also called drug repurposing) in the therapeutics of the novel coronavirus disease which emerged in 2019 (COVID-19).
Rodrigues, Pedro da Fonseca Soares, Thomaz, Douglas Vieira   +1 more
core   +2 more sources

Strategic Preparedness of Broad-Spectrum Antivirals for Rapid Response Towards Next Pandemics. [PDF]

Small Sci
Nanoengineered broad‐spectrum antivirals (BSAs) represent a transformative approach to pandemic preparedness. Unlike virus‐specific drugs requiring separate development, BSAs act across multiple viral families through nanoengineering strategies that enhance solubility, bioavailability, and host‐targeted activity.
N SR, Jin GW, Choy JH.
europepmc   +2 more sources

Favipiravir-induced fever in coronavirus disease 2019: A report of two cases

International Journal of Infectious Diseases, 2020
Favipiravir, an antiviral agent, is undergoing clinical trials for treating novel coronavirus disease 2019 (COVID-19). Here, we report two cases of COVID-19 with favipiravir-induced fever.
Hiroyuki Takoi, Yuki Togashi, Daiki Fujimori, Haruki Kaizuka, Shunsuke Otsuki, Takuya Wada, Yoshikazu Takeuchi, Shinji Abe   +7 more
doaj   +1 more source

A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?

Journal of Virus Eradication, 2020
Background: Repurposing broad-spectrum antivirals is an immediate treatment opportunity for 2019 coronavirus disease (COVID-19). Favipiravir is an antiviral previously indicated for influenza and Ebola, which has shown some promise in early trials for ...
Victoria Pilkington, Toby Pepperrell, Andrew Hill   +2 more
doaj   +1 more source

Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis

Drug Delivery, 2022
Favipiravir, an RNA-dependent RNA polymerase (RdRp) inhibitor, is used to treat patients infected with influenza virus and most recently with SARS-CoV-2.
Ayca Yildiz Pekoz, Ozlem Akbal Dagistan, Hanan Fael, Meltem Culha, Aybige Erturk, Nur Sena Basarir, Gokben Sahin, Muge Serhatli, Gamze Cakirca, Saban Tekin, Leyla Semiha Sen, Mustafa Sevim, Lutfiye Mulazimoglu Durmusoglu, Berrak C. Yegen   +13 more
doaj   +1 more source

Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals

Saudi Pharmaceutical Journal, 2023
Purpose: We aimed to evaluate the cost effectiveness of Favipiravir treatment versus standard of care (SC) in moderately to severely ill COVID-19 patients from the Saudi healthcare payer perspective.
Ahmad Alamer, Abdulaali R. Almutairi, Shiraz Halloush, Ahmed Al-jedai, Ahmed Alrashed, Mashael AlFaifi, Yahya Mohzari, Malak Almutairi, Fatimah AlHassar, Jude Howaidi, Wedad Almutairi, Ivo Abraham, Nimer Alkhatib   +12 more
doaj   +1 more source

A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test

International Journal of Infectious Diseases, 2021
As of October 2020, there is still no specific drug to treat COVID-19 as it rages worldwide. Favipiravir, indicated for the treatment of new and re-emerging influenza infections, has been suggested to be effective against SARS-CoV-2, although this is not
Yushi Murai, Hitoshi Kawasuji, Yusuke Takegoshi, Makito Kaneda, Kou Kimoto, Akitoshi Ueno, Yuki Miyajima, Koyomi Kawago, Yasutaka Fukui, Chika Ogami, Ippei Sakamaki, Yasuhiro Tsuji, Yoshitomo Morinaga, Yoshihiro Yamamoto   +13 more
doaj   +1 more source

Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation

BMC Chemistry, 2023
Favipiravir and remdesivir have been included in the COVID-19 treatment guidelines panel of several countries. The main objective of the current work is to develop the first validated green spectrophotometric methods for the determination of favipiravir ...
Afnan S. Batubara, Ahmed H. Abdelazim, Ahmed A. Almrasy, Mohammed Gamal, Sherif Ramzy   +4 more
doaj   +1 more source

Therapeutic efficacy of favipiravir against Bourbon virus in mice [PDF]

, 2019
Bourbon virus (BRBV) is an emerging tick-borne RNA virus in the orthomyxoviridae family that was discovered in 2014. Although fatal human cases of BRBV have been described, little is known about its pathogenesis, and no antiviral therapies or vaccines ...
Bailey, Thomas, Boon, Adrianus C. M., Bricker, Traci L, Diamond, Michael S, Gounder, Anshu P, Jagger, Brett W, Janowski, Andrew B, Kwon, Jennie H, Shafiuddin, Md., Wang, David, Williams, Graham D, Zhao, Guoyan   +11 more
core   +3 more sources